Motolimod

DB12303InvestigationalSmall molecule

Motolimod has been used in trials studying the treatment of Lymphoma, Tongue Cancer, Ovarian Cancer, Adult Solid Neoplasm, and Fallopian Tube Cancer, among others.

Mechanism: Pharmacologically active on Toll-like receptor 8
Curator reviewed
Formula / weight: C₂₈H₃₄N₄O₂ · 458.606 g/mol (avg)
Also known as: {2-amino-8-[4-(pyrrolidinylcarbonyl)phenyl](3H-benzo[f]azepin-4-yl)}-N,N-dipropycarboxamide
Code names: VTX-2337 · VTX-378

Resolves to

Compound

UNIIWP6PY72ZH3CAS926927-61-9ChEMBLCHEMBL3301618ChEBI755299PubChem16049404

Structure

InChIKeyQSPOQCXMGPDIHI-UHFFFAOYSA-NSMILESCCCN(CCC)C(=O)C1=CC2=CC=C(C=C2N=C(N)C1)C1=CC=C(C=C1)C(=O)N1CCCC1

Targets

Q9NR97TLR8

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

11Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Motolimod, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account